ADVERTISEMENT

A Cunning Predator

Therapies improve for asbestos-caused cancer.

BY KATY HUMAN
PUBLISHED WEDNESDAY, SEPTEMBER 27, 2006
Talk about this article with other patients, caregivers, and advocates in the Lung CURE discussion group.
When Klaus Brauch began experiencing chest pain six years ago, he assumed it was his heart. He was working a high-stress job and his blood pressure had been off the charts. Doctors eventually diagnosed him with congestive heart failure and the software company manager prepared for life with a diseased heart—not cancer. Certainly not a rare cancer called mesothelioma. “Misdiagnosis is how it starts for so many people,” says Brauch, now 56, of Huntington Beach, California. “It becomes a wild goose chase.” Six months after Brauch experienced his first symptoms, doctors confirmed a diagnosis of mesothelioma.  

About 3,000 Americans will be diagnosed with mesothelioma in 2006, and the rising incidence of mesothelioma outside the United States isn’t expected to peak for another 10 to 20 years. While lung cancer affects the airways of the lung itself, pleural mesothelioma affects the tissues lining the lung and the chest and accounts for the majority of mesothelioma patients. Mesothelioma can also grow across the thin mesothelial tissue that lines the abdomen (peritoneum) or, rarely, the heart or testicles.

Mesothelioma is unusual in that it’s tightly linked with an environmental cause—asbestos exposure, which accounts for more than 80 percent of cases. A variety of migration mechanisms have been proposed to explain how inhaled asbestos fibers reach the pleural surface, but none have been proven. While inhaled asbestos fibers can lead to pleural mesothelioma, it’s believed that peritoneal mesothelioma develops from asbestos fibers that are swallowed and become lodged in the digestive tract. If a person has been exposed to asbestos, smoking greatly increases his or her risk of asbestos-related lung cancer, though smoking does not appear to affect pleural mesothelioma risk. Research also points to a possible connection between asbestos and laryngeal cancer.

View Illustration: Mesothelioma: Cause & EffectMost mesothelioma patients worked or lived in a place where they were exposed to asbestos. Brauch handled asbestos-containing materials as a teenager during a summer contractor job, and later while refinishing a house.

Researchers believe asbestos triggers cancer in several ways, says Harvey Pass, MD, a leading mesothelioma expert and chief of thoracic surgery and thoracic oncology at New York University Medical Center. The mineral’s microscopic fibers may physically injure cells during replication, causing genetic changes that lead to cancer. Asbestos fibers may also contain elements that chemically interact with cells, damaging genetic material and thus leading to cancer. Finally, the fibers may trigger immune system changes that lead to cancer. 

Typical mesothelioma patients worked in shipyards or as miners, but Brauch’s story isn’t unusual, says Jill Dyken, PhD, an environmental health scientist with the federal Agency for Toxic Substances and Disease Registry. Family members of miners and defense workers have also developed the disease—many with relatively little exposure. “We don’t know what level of exposure is enough to cause mesothelioma,” says Dr. Dyken.

Such epidemiological questions are vexing in part because mesothelioma tends to appear 30 to 50 years after asbestos exposure. That can also foil diagnosis, says Dr. Pass. Doctors often confuse the earliest symptoms, including shortness of breath, with heart disease or a sign of aging, so months often pass before a patient is correctly diagnosed. Delayed diagnosis is just one of several factors that makes mesothelioma a devastatingly effective killer, says Dr. Pass. It’s hard to remove surgically and is resistant to radiation and chemotherapy. Overall, fewer than 10 percent of patients survive five years after diagnosis.

Until recently, many doctors advised patients to forego grueling treatments and just live the rest of their lives as comfortably as possible. But Dr. Pass says they’re making progress. New combinations of chemotherapy agents have been found to shrink tumors up to 40 percent of the time, and surgeons are perfecting techniques for removing diseased tissue. Selective use of radiation can even delay recurrence for some patients. “Treatments are better now,” says Dr. Pass. “There is no excuse for a doctor to say, ‘There’s nothing to do.’ ” Researchers are finding ways to diagnose and track the disease, and they’re uncovering the cancer’s cellular quirks to better design new therapies. 

Beginning in 1998, one of Danielle Rosinski’s lungs kept filling up with fluid. “Every year I had it drained and nothing showed up,” says Rosinski, a 66-year-old mesothelioma patient from Westland, Michigan. In 2003, her pulmonologist suggested pleurodesis—sprinkling talc into the space between her chest and lungs to keep fluid from accumulating. That’s when he saw the cancer. “When he told me I could live a year, well, that was a big blow,” says Rosinski, noting she’s reached nearly three years now.

Talk about this article with other patients, caregivers, and advocates in the Lung CURE discussion group.
ADVERTISEMENT
Cure Connections
Related Articles
Addario Lung Cancer Foundation: Striving to Solve Young Lung Cancer
BY BONNIE J. ADDARIO
As a lung cancer survivor and advocate for current patients, I have always been outspoken about the need for greater lung cancer awareness.
Earlier is Better: Managing Side Effects from Immunotherapy in Lung Cancer
BY ANDREW J. ROTH
CURE sat down with Suresh S. Ramalingam to discuss important considerations for patients, caregivers, nurses and physicians when treatment with an immunotherapy begins.
Merging a Passion for Research With a Dedication to Patient Care
BY ANDREW J. ROTH
Hirsch Honored With Addario Lectureship Award in Lung Cancer
Survivor Spotlight: Nancy Carpenter
BY FREE TO BREATHE
Nancy Carpenter was FreeToBreathe's featured survivor of the month for April.
FDA Approval Sought for New Treatment of NSCLC Subset
BY SILAS INMAN
Rolling submission of a new drug application for rociletinib has been initiated for patients with EGFR T790M-positive metastatic NSCLC following prior treatment with an EGFR-targeted therapy.
Related Videos
D. Ross Camidge on the Development of a New Lung Cancer Drug
BY D. ROSS CAMIDGE
D. Ross Camidge, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the development of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK).
Bonnie J. Addario Discusses Unmet Needs in Lung Cancer Care
BY BONNIE J. ADDARIO
Bonnie J. Addario discusses unmet needs in lung cancer care today.
Janet Freeman-Daily on Genomic Testing for Lung Cancer Patients
BY JANET FREEMAN-DAILY
Janet Freeman-Daily, a patient with metastatic lung cancer and a CURE contributor, discusses the importance of genomic testing for patients with lung cancer.
Jyoti D. Patel on Treating Brain Metastases in Lung Cancer Patients
BY JYOTI D. PATEL
Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the treatment of patients with lung cancer with brain metastases.
Jyoti D. Patel on the Progress of Immunotherapy in NSCLC
BY JYOTI D. PATEL
Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.
$auto_registration$
VSEO N/A